Optimer Pharmaceuticals to Present at Investor Conferences in June
Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced today that the Company plans to present at the following two investor conferences:
The 2nd Annual Piper Jaffray London Health Care Conference, June 20, 2007 at 12:40 p.m. British Summer Time (7:40 a.m. Eastern Time) at the Great Eastern Hotel in London.
Jefferies Healthcare Conference, June 27, 2007 at 3:10 p.m. Eastern Time at the Mandarin Oriental in New York City.
A live audio webcast of these presentations will be available on the Company’s website at www.optimerpharma.com, on the investors’ page. Replays of these presentations will be available at the same site for thirty days after the meeting.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products for the treatment of serious infections. Optimer currently has two late-stage anti-infective product candidates. OPT-80, also known as PAR-101 or Difimicin, is being developed for the treatment of Clostridium difficile-associated diarrhea, the most common hospital-acquired diarrhea. Prulifloxacin (OPT-99) is an antibiotic currently in two Phase 3 trials for the treatment of travelers’ diarrhea, a form of infectious diarrhea. Additional information regarding Optimer can be found at http://www.optimerpharma.com.
Forward-looking Statements
Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to OPT-80 and the expansion of the number of clinical sites for our related Phase 3 studies, Prulifloxacin, CDAD, and the timing of clinical trials and anticipated results and regulatory activities. Words such as “believes,”"anticipates,”"plans,”"expects,”"intend,”"will,”"goal” and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer’s business including, without limitation, risks relating to: the timing, progress and likelihood of success of our product research and development programs, the timing and status of our preclinical and clinical development of potential drugs and other risks detailed in Optimer’s filings with the Securities and Exchange Commission.